@drstephanieyomo's perimenopause claims, fact-checked

What did @drstephanieyomo actually say?

The creator made three core claims about perimenopause: it can begin in the mid-to-late 30s, it involves more than hot flashes, and symptoms can last up to 10 years. She also said that "optimizing your hormones can make you feel a lot better" and credited her Lifeforce membership with giving her "more energy" and "less brain fog." This is a sponsored post for Lifeforce, a telehealth hormone testing service. That context matters when weighing how she frames the problem and the solution.

Worth noting upfront: the transcript is riddled with what appears to be speech-to-text errors. She says "pyramidal pals" and "minipals" throughout, which are clearly garbled renderings of "perimenopause" and "menopause." This does not change the substance of her claims, but it does suggest the content was not closely reviewed before posting.

Does the science back this up?

Mostly, yes, on the biology. The claim that perimenopause can start in the mid-to-late 30s is real but requires context. Most women enter perimenopause between 45 and 55, but the transition can begin earlier. The claim about symptom duration is also supported, though "up to 10 years" is the outer edge, not the median.

The SWAN study (Study of Women's Health Across the Nation, Avis et al., 2015, JAMA Internal Medicine) followed over 1,400 women and found that the median duration of vasomotor symptoms, meaning hot flashes and night sweats, was 7.4 years from the final menstrual period. Some women experienced symptoms for more than a decade. A separate analysis from the same cohort found that symptoms starting before the final menstrual period lasted even longer. So "up to 10 years" is defensible.

The broader symptom list she mentions, including fatigue, joint pain, and brain fog, is also supported in clinical literature. The SWAN study and other cohort data confirm these are common perimenopausal complaints, not just anecdotal.

What did they get wrong (or right)?

The 30s onset claim deserves more precision than she gives it. Perimenopause in the mid-to-late 30s does happen, but it is not common. The average age of onset is around 47 (Santoro et al., 2016, Journal of Clinical Endocrinology and Metabolism). Framing it as a "surprising fact" without clarifying that earlier onset is the exception, not the rule, could cause unnecessary alarm for younger viewers.

She deserves credit for expanding the symptom conversation beyond hot flashes. Clinicians have historically underrecognized perimenopausal symptoms like joint pain and cognitive complaints. A 2020 review in Maturitas (Greendale et al.) confirmed that brain fog and musculoskeletal symptoms are underdiagnosed during this transition. So that part of her message is genuinely useful.

Where she oversimplifies: the jump from "here are your symptoms" to "Lifeforce fixed mine" is a testimonial, not a clinical argument. The claim that hormone optimization will help is plausible for some women, but hormone therapy is not appropriate for everyone, and the evidence base varies by symptom type and individual health profile.

What should you actually know?

If you are in your late 30s or 40s and noticing changes in sleep, mood, energy, or menstrual patterns, it is worth talking to a clinician. Perimenopause is a real and often underdiagnosed transition. Hormone testing can be part of that conversation, but a single blood draw is not a complete picture. Estrogen and progesterone levels fluctuate significantly during perimenopause, sometimes day to day, so timing and context matter.

Hormone therapy (HT) for perimenopausal symptoms has a reasonable evidence base for certain women. The Menopause Society (formerly NAMS) updated its 2022 position statement to affirm that HT is appropriate for healthy women under 60 or within 10 years of menopause onset who have bothersome symptoms and no contraindications. But that recommendation applies to conventional, FDA-approved formulations, not compounded preparations, which have a different regulatory and evidence profile.

A direct-to-consumer telehealth platform that sends a phlebotomist to your home and recommends a hormone plan is not the same as a comprehensive evaluation by a gynecologist or endocrinologist who knows your full history. It may be a useful starting point for some people, but it should not be treated as a substitute for that relationship.